Changes in the Penetration Rate of Biosimilar Infliximab Within Japan Using a Japanese Claims Database

Abstract

Purpose Infliximab, which was approved in 2002, had its first biosimilar launched in 2014 across Japan. However, the penetration rate of this biosimilar remains unclear given the limited data regarding its current clinical use throughout Japan. This study was conducted to describe the current clinical characteristics of patients receiving infliximab and the penetration rate of the reference infliximab and/or biosimilar infliximab using a Japanese administrative claims database. Patients and Methods This retrospective, descriptive study utilized the Japan Medical Data Vision database, a nationwide hospital-based database. Data on patients receiving infliximab recorded from April 2008 to March 2019 were extracted from the database. Patient characteristics of the reference and biosimilar infliximab groups and penetration rates according to fiscal year, target diseases diagnosis, and subsidy for intractable diseases were examined. Results A total of 9735 patients were extracted for analysis, among whom 92% (n=8950) and 8% (n=785) received only reference infliximab and its biosimilar, respectively. Both groups exhibited similar clinical characteristics. The biosimilar penetration rate increased from 0.8% in 2014 to 22.5% in 2018, with overall penetration rates throughout the period according to diagnosis (with or without subsidy) being 14.4% (with, 4.1%; without, 16.4%), 4.7% (with, 3.7%; without, 10.6%), 5.7% (with, 4.5%; without, 13.5%), and 7.5% (with, 4.4%; without, 8.2%) for rheumatoid arthritis, Crohn’s disease, ulcerative colitis, and psoriasis, respectively. Conclusion Biosimilar infliximab is prescribed for patients with similar characteristics to reference infliximab. Despite the increasing penetration rates according to target disease, they remain much lower among patients receiving subsidy for intractable disease than among those who do not.

Clinical Utilization of Generic Drugs and Biosimilars for Ulcerative Colitis Treatment: Insights from a Nationwide Database Study in Japan

“…This shift is expected to reduce medical expenses and patients' financial burdens [17]. Similar to our findings, another retrospective study using a different database also reported a lower penetration rate (22.5%) for IFX biosimilar in 2018 [18].…”

A randomized, single-dose, pharmacokinetic equivalence study comparing MB02 (proposed biosimilar) and reference bevacizumab in healthy Japanese male volunteers

“…However, access to this treatment option is limited by the high cost of the treatment, and, currently, the arrival of bevacizumab biosimilars may mitigate cost barriers for patients and increase access to such an important therapy in oncology [ 4 ]. Particularly, in Japan, biosimilars are approximately 30% cheaper than their reference products and can provide a solution for reducing national health-care costs [ 5 ].…”

Long-term effectiveness and safety of infliximab-biosimilar: A multicenter Phoenix retrospective cohort study

“…The market share of IFX-BS was 89% in the U.K [ 20 ], 76% in France [ 21 ], 85.3% in South Korea [ 22 ], and 9.7% in the U.S [ 23 ]. In Japan, the market share of IFX-BS has been gradually increasing and accounted for 25% of the total IFX in 2018 [ 24 ]. Despite the increasing use of IFX-BS worldwide, clinical data on the long-term effectiveness of IFX-BS treatment, such as the five years treatment persistence rate, is insufficient.…”